Report
David Nierengarten ...
  • Matthew Barcus

1Q21 Financials; It’s TEA Time with New TEAD Platform

Underlying
SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company's product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. The company's second product candidate is mirdametinib, an oral, small molecule MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, a rare tumor of the peripheral nerve sheath that causes pain and disfigurement.

Provider
Wedbush
Wedbush

Since our founding in 1955, Wedbush has been a leader in the financial industry providing our clients with a wide range of services; including institutional sales, correspondent clearing services, equity research, corporate and municipal finance, equity market making, fixed income trading, prime brokerage, and wealth management. Headquartered in Los Angeles, with 100 registered offices, the firm focuses on dedicated service, client financial safety, continuity, and advanced technology.

Analysts
David Nierengarten

Matthew Barcus

Other Reports on these Companies
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
Wedbush Research
Other Reports from Wedbush
Jay McCanless
James Hardiman ...
  • Matthew McCartney
  • Sean Wagner
Brian Violino ...
  • David Chiaverini
  • Hersh Shintre
  • Peter Winter
Other Reports from these Analysts
David Nierengarten
David Nierengarten
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

ResearchPool Subscriptions

Get the most out of your insights

Get in touch